m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT03146
 [1]
m6A modification USP38 USP38 METTL7B Methylation : m6A sites Indirect Inhibition Histone modification H4K5la HDAC3 Downstream Gene
m6A Modification:
m6A Regulator Thiol S-methyltransferase TMT1B (METTL7B) WRITER
 Regulator Info 
m6A Target Ubiquitin carboxyl-terminal hydrolase 38 (USP38)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Histone modification (HistMod)
Epigenetic Regulator Histone deacetylase 3 (HDAC3) ERASER View Details
Regulated Target Histone H4 lysine 5 lactylation (H4K5la) View Details
Crosstalk Relationship m6A  →  Histone modification Inhibition
Crosstalk Mechanism m6A modification indirectly regulates histone modification through downstream signaling pathways
Crosstalk Summary METTL7B suppressed the expression of Ubiquitin carboxyl-terminal hydrolase 38 (USP38) via m6A dependent mRNA degradation, resulting in increasing ubiquitylation of HDAC3, which decreasing H3K18la and Histone H4 lysine 5 lactylation (H4K5la) level.
In-vitro Model
 H9c2(2-1) Normal Rattus norvegicus CVCL_0286
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Histone deacetylase 3 (HDAC3) 19 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name CHR-3996 Phase 1/2 [2]
Synonyms
CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 7 nM
External Link
CID: 49857317
TTD: D06TKI
DrugBank: DB15419
 Compound Name PMID29671355-Compound-57 Patented [3]
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
TTD: D0UD9R
 Compound Name Diaryl amine derivative 4 Patented [4]
Synonyms
PMID28092474-Compound-9
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 76 nM
External Link
TTD: D0XN2W
 Compound Name PMID29671355-Compound-59 Patented [3]
MOA Inhibitor
Activity IC50 = 43 nM
External Link
CID: 130319551
TTD: D0C9NX
 Compound Name PMID29671355-Compound-55 Patented [3]
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
CID: 60198673
TTD: D0OU0J
 Compound Name PMID29671355-Compound-11 Patented [3]
MOA Inhibitor
Activity IC50 = 546 nM
External Link
CID: 118005782
TTD: D0EH2K
 Compound Name PMID29671355-Compound-9 Patented [3]
MOA Inhibitor
Activity IC50 = 158 nM
External Link
CID: 57381425
TTD: D0Q1QY
 Compound Name PMID29671355-Compound-8 Patented [3]
MOA Inhibitor
Activity IC50 = 22800 nM
External Link
TTD: D0LN1T
 Compound Name PMID29671355-Compound-61 Patented [3]
MOA Inhibitor
Activity IC50 = 839.3 nM
External Link
TTD: D0JB4S
 Compound Name PMID29671355-Compound-44 Patented [3]
MOA Inhibitor
Activity IC50 < 150 nM
External Link
CID: 72710871
TTD: D0N2DK
 Compound Name PMID29671355-Compound-56 Patented [3]
MOA Inhibitor
Activity IC50 = 28.7 nM
External Link
CID: 56965342
TTD: D0CH8Q
 Compound Name PMID29671355-Compound-67 Patented [3]
MOA Inhibitor
Activity IC50 = 10000 nM
External Link
CID: 60201048
TTD: D0M0RE
 Compound Name PMID29671355-Compound-31 Patented [3]
MOA Inhibitor
Activity IC50 = 0.6 nM
External Link
CID: 90479372
TTD: D0DI9S
DrugBank: DB14979
 Compound Name PMID29671355-Compound-21 Patented [3]
MOA Inhibitor
Activity IC50 = 10300 nM
External Link
CID: 86295624
TTD: D0LP1K
 Compound Name PMID29671355-Compound-62 Patented [3]
MOA Inhibitor
Activity IC50 = 100 to 500 nM
External Link
TTD: D07WAT
 Compound Name PMID29671355-Compound-43 Patented [3]
MOA Inhibitor
Activity IC50 = 140 nM
External Link
CID: 118515590
TTD: D0BP8I
 Compound Name PMID29671355-Compound-25 Patented [3]
MOA Inhibitor
Activity IC50 = 1310 nM
External Link
CID: 126569528
TTD: D0RA0D
 Compound Name RGFP966 Investigative [5]
Synonyms
RGFP-966
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 80 nM
External Link
CID: 56650312
TTD: D00HXX
 Compound Name droxinostat Investigative [6]
Synonyms
NS-41080; NS41080
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 568416
TTD: D00VXM
References
Ref 1 METTL7B-induced histone lactylation prevents heart failure by ameliorating cardiac remodelling. J Mol Cell Cardiol. 2025 May;202:64-80. doi: 10.1016/j.yjmcc.2025.03.006. Epub 2025 Mar 9.
Ref 2 A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94. doi: 10.1158/1078-0432.CCR-11-3165.
Ref 3 HDAC inhibitors: a 2013-2017 patent survey. Expert Opin Ther Pat. 2018 Apr 19:1-17. doi: 10.1080/13543776.2018.1459568. Online ahead of print.
Ref 4 Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
Ref 5 HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2647-52.
Ref 6 Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther. 2010 Jan;9(1):246-56.